ORBIMED ADVISORS LLC 13D and 13G filings for Kala Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-10-14 5:00 pm Sale | 2021-10-12 | 13G | Kala Pharmaceuticals, Inc. KALA | ORBIMED ADVISORS LLC | 0 0.000% | -188,568 (Position Closed) | Filing |
| 2021-03-01 6:09 pm Unchanged | 2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | ORBIMED ADVISORS LLC | 188,568 8.410% | 0 (Unchanged) | Filing |
| 2021-02-12 4:53 pm Purchase | 2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | ORBIMED ADVISORS LLC | 188,568 8.410% | 50,654 (+36.73%) | Filing |